AXGT

Axovant Sciences Ltd.

A biopharmaceutical company that scooped up drug candidates shelved by larger pharmaceutical firms and tried to bring them to patients, Axovant focused early on Alzheimer's disease and other neurological conditions before pivoting to gene therapies for disorders like Parkinson's. It was founded in 2014 by entrepreneur Vivek Ramaswamy as part of Roivant Sciences' family of "Vant" subsidiaries, which shared resources while each chased a different therapeutic field. Its stock ticker, AXON, was a nod to the nerve fibers central to the brain conditions it studied.

No Schedule 13D or 13G filings recorded.